英文
論文
1. Yoshimasa Y, Okamoto M, Yamada K, Nishimura H, Sakamoto Y, Kuzuya H, Imura H. Purification of Insulin Receptor from Human Placental Membranes. Jpn Arch Int Med 33: 337-347, 1986
2. Yoshimasa Y, Kakehi T, Yamada K, Nishimura H, Ida T, Takeda J, Kosaki A, Kato Y, Seino Y, Kuzuya H, Imura H, Kikuchi K, Seino S, Bell GI. Insulin Receptors and Its Gene in Pathologic State. J Japan Diab Soc 29: 1179-1180, 1986
3. Kakehi T, Kuzuya H, Yoshimasa Y, Yamada K, Okamoto M, Nishimura H, Imura H. Binding and tyrosine kinase activities of the insulin receptor on Epstein-Barr virus transformed lymphocytes from patients with Werner's syndrome. J Gerontol 43: 40-45, 1988
4. Tsukahara H, Kikuchi K, Kuzuya H, Ito E, Oda Y, Kosaki A, Kakehi T, Nishimura H, Yamada K, Yoshimasa Y, Imura H. Insulin resistance in a boy with congenital generalized lipodystrophy. Pediatr Res 24(6): 668-672, 1988
5. Kosaki A, Kuzuya H, Yoshimasa Y, Yamada K, Okamoto M, Nishimura H, Kakehi T, Takeda J, Seino Y, Imura H. Regulation of glucose-transporter gene expression by insulin in cultured human fibroblasts. Diabetes 37(11): 1583-1586, 1988
6. Nishimura H, Kuzuya H, Okamoto M, Yoshimasa Y, Yamada K, Ida T, Kakehi T, Imura H. Change of insulin action with aging in conscious rats determined by euglycemic clamp. Am J Physiol 254: E92-E98, 1988
7. Kakehi T, Hisatomi A, Kuzuya H, Yoshimasa Y, Okamoto M, Yamada K, Nishimura H, Kosaki A, Nawata H, Umeda F, Imura H. Defective processing of insulin-receptor precursor in cultured lymphocytes from a patient with extreme insulin resistance. J Clin Invest 81: 2020-2022, 1988
8. Nishimura H, Kuzuya H, Okamoto M, Yamada K, Kosaki A, Kakehi T, Inoue G, Kono S, Imura H. Postreceptor defect in insulin action in streptozotocin-induced diabetic rats. Am J Physiol 256: E624-E630, 1989
9. Kono S, Kuzuya H, Okamoto M, Nishimura H, Kosaki A, Kakehi T, Okamoto M, Inoue G, Maeda I, Imura H. Changes in insulin receptor kinase with aging in rat skeletal muscle and liver. Am J Physiol 259: E27-E35, 1990
10. Simpson IA, Cushman SW, Egan JJ, Habberfield AD, Londos C, Nishimura H, Saltis J. Hormonal regulation of glucose transport in rat adipose cells. Biochem Soc Trans 18:1123-1125, 1990
11. Kakehi T, Kuzuya H, Kosaki A, Yamada K, Yoshimasa Y, Okamoto M, Nishimura H, Nishitani H, Saida K, Kuno S, Imura H. Binding activity and autophosphorylation of the insulin receptor from patients with myotonic dystrophy. J Lab Clin Med 115: 688-695, 1990
12. Okamoto M, Okamoto M, Nishimura H, Kosaki A, Kono S, Inoue G, Maeda I, Kubota M, Hayashi T, Kuzuya H, Imura H. Insulin-stimulated glucose uptake and fasting blood glucose. Endocrinol Jpn 38(4): 421-427, 1991
13. Nishimura H, Saltis J, Habberfield AD, Garty NB, Greenberg AS, Cushman SW, Londos C, Simpson IA. Phosphorylation state of the GLUT4 isoform of the glucose transporter in subfractions of the rat adipose cell: effects of insulin, adenosine, and isoproterenol. Proc Natl Acad Sci USA 88: 11500-11504, 1991
14. Kosaki A, Kuzuya H, Nishimura H, Inoue G, Okamoto M, Kakehi T, Okamoto M, Kono S, Maeda I, Kubota M, Imura H. Regulation of glucose transporter synthesis in cultured human skin fibroblasts. Mol Cell Endocrinol 75: 189-196, 1991
15. Vannucci SJ, Nishimura H, Satoh S, Cushman SW, Holman GD, Simpson IA. Cell surface accessibility of GLUT4 glucose transporters in insulin-stimulated rat adipose cells. Modulation by isoprenaline and adenosine. Biochem J 288: 325-330, 1992
16. Nishimura H, Kuzuya H, Kosaki A, Okamoto M, Okamoto M, Kono S, Inoue G, Maeda I, Imura H. Monoclonal antibodies possibly recognize conformational changes in the human erythrocyte glucose transporter. Biochem J 281: 103-106, 1992
17. Nishimura H, Zarnowski MJ, Simpson IA. Glucose transporter recycling in rat adipose cells. Effects of potassium depletion. J Biol Chem 268: 19246-19253, 1993
18. Satoh S, Nishimura H, Clark AE, Kozka IJ, Vannucci SJ, Simpson IA, Quon MJ, Cushman SW, Holman GD. Use of bismannose photolabel to elucidate insulin-regulated GLUT4 subcellular trafficking kinetics in rat adipose cells. Evidence that exocytosis is a critical site of hormone action. J Biol Chem 268(24): 17820-17829, 1993
19. Nishimura H, Pallardo FV, Seidner GA, Vannucci S, Simpson IA, Birnbaum MJ. Kinetics of GLUT1 and GLUT4 glucose transporters expressed in Xenopus oocytes. J Biol Chem 268(12): 8514-8520, 1993
20. Kono S, Kuzuya H, Yamada K, Yoshimasa Y, Okamoto M, Nishimura H, Kosaki A, Inoue G, Hayashi T, Imura H. Preparation of anti-phosphoserine and anti-phosphothreonine antibodies and their application in the study of insulin- and EGF-induced phosphorylation. Biochem Biophys Res Commun 190: 283-288, 1993
21. Sako Y, Inoue T, Sugawara A, Nishimura H, Koshimura O, Morimoto A, Koishi H. Thyroid function in the aged of 80 years and over, actively living at home. Proceedings of the XVth Congress of the international Association of Gerontology 769-773, 1993
22. Nishimura H, Simpson IA. Staurosporine inhibits phorbol 12-myristate-13-acetate- and insulin-stimulated translocation of GLUT1 and GLUT4 glucose transporters in rat adipose cells. Biochem J 302: 271-277, 1994
23. Kraemer FB, Sather SA, Park B, Sztalryd C, Natu V, May K, Nishimura H, Simpson IA, Cooper AD, Cushman SW. Low density lipoprotein receptors in rat adipose cells: subcellular localization and regulation by insulin. J Lipid Research 35: 1760-1772, 1994
24. Adachi M, Nishimura H, Inoue T, Sako Y. Adult T-cell leukemia with various abnormalities in endocrine and metabolic systems. British J Haematol 87: 853-855, 1994
25. Nishimura H, Nishino K, Inoue T, Koshimura O, Sako Y. Effects of Insulin and a Phosphodiesterase (PDE) Inhibitor on Microcirculation of the Foot Skin in NIDDM patients. Diabetes 45: 17A, 1996
26. Nishimura H, Shintani M, Yamamoto Y, Suga J, Tanaka T, Takaya K, Yoshimasa Y, Nakao K. Leptin Decreases Protein and mRNA Levels of GLUT4 in Rat Adipocytes. Diabetes 46: 59A, 1997
27. Shintani M, Nishimura H, Yamamoto Y, Suga J, Tanaka T,Hanaoka I, Yoshimasa Y, Nishi S, Nakao K. Differential Regulation of Isoproterenol and Troglitazone on Leptin and GLUT4 in Rat Adipocytes. Diabetes 46: 86A, 1997
28. Azuma N, Nishimura H, Yamamoto Y, Suga J, Shigemoto M, Nishi S, Yoshimasa Y. Significance of the Trp64Arg Mutation of 3-Adrenergic Receptor Gene in Insulin Resistance. Diabetes 46: 168A, 1997
29. Masuzaki H, Ogawa Y, Hosoda K, Miyawaki T, Hanaoka I, Hiraoka J, Yasuno A, Nishimura H, Yoshimasa Y, Nishi S, Nakao K. Glucocorticoid regulation of leptin synthesis and secretion in humans: elevated plasma leptin levels in Cushing's syndrome. J Clin Endocrinol Metab 82: 2542-2547, 1997
30. Masuzaki H, Ogawa Y, Sagawa N, Hosoda K, Matsumoto T, Mise H, Nishimura H, Yoshimasa Y, Tanaka I, Mori T, Nakao K. Nonadipose tissue production of leptin: leptin as a novel placenta-derived hormone in humans. Nature Med 3:1029-1033, 1997
31. Matsuoka N, Ogawa Y, Hosoda K, Matsuda J, Masuzaki H, Miyawaki T, Azuma N, Natsui K, Nishimura H, Yoshimasa Y, Nishi S, Thompson DB, Nakao K. Human leptin receptor gene in obese Japanese subjects: evidence against either obesity-causing mutations or association of sequence variants with obesity. Diabetologia 40: 1204-1210, 1997
32. Shigemoto M, Nishi S, Ogawa Y, Isse N, Matsuoka N,Tanaka T, Azuma N, Masuzaki H, Nishimura H, Yoshimasa Y, Hosoda K, NakaoK. Molecular screening of both th epromoter and the protein coding regions in the human ob gene in Japanese obese subjects with non-insulin-dependent diabetes mellitus (NIDDM). Eur J Endocrinol 137: 511-513, 1997
33. Matsuda J, Hosoda K, Itoh H, Son C, Doi K, Tanaka T, Fukunaga Y, Inoue G, Nishimura H, Yoshimasa Y, Yamori Y, Nakao K. Cloning of rat uncoupling protein-3 and uncoupling protein-2 cDNAs: their gene expression in rats fed high-fat diet. FEBS Lett 418:200-204, 1997
34. Azuma N, Yoshimasa Y, Nishimura H, Yamamoto Y, Masuzaki H, Suga J, Shigemoto M, Matsuoka N, Tanaka T, Sattoh N, Igaki T, Miyamoto Y, Itoh H, Yoshimasa T, Hosoda K, Nishi S, Nakao K. The significance of the Trp64Arg mutation of the B3-adrenergic receptor gene in impaired glucose tolerance, non-insulin-dependent diabetes mellitus and insulin resistance in Japanese subjects. Metabolism 47: 456-460, 1998
35. Yonemitsu Y, Shintani M, Yamamoto Y, Matsuoka N, Suga J, Hosoda K, Yoshimasa Y, Nishimura H. Effect of Leptin and Troglitazone on Glucose Uptake in L6 Myotcytes. Diabetes 47: A272, 1998
36. Shintani M, Nishimura H, Yonemits S, Hosoda K, Hiraoka J, Matsuoka N, Yoshimasa Y, Nishi S, Nakao K. Differential Regulation of Free Fatty Acid and Troglitazone on Leptin and GLUT4 in Rat Adipocytes. Diabetes 47: 319A, 1998
37. Matsuda J, Hosoda K, Itoh H, Son C, Doi K, Hanaoka I, Inoue G, Nishimura H, Yoshimasa Y, Yamori Y, Odaka H, Nakao K. Increased adipose expression of uncoupling protein-3 gene by thizolidinediones in Wister fatty rats and in cultured adipocytes. Diabetes 47:1809-1814, 1998
38. Tanaka,T, Itho H, Doi K, Fukunaga Y, Hosoda K, Shintani M, Yamashita J, Chun T-H, Inoue M, Masatsugu K, Sawada N, Saito T, Inoue G, Nishimura H, Yoshimasa Y, Nakao K. Down regulation of peroxisome proliferator-activated receptorg expressionn by inflammatory cytokinesn and its reversal by thiazolidinediones. Diabetologia 42:702-710, 1999
39. Shintani M, Nishimura H, Akamizu T, Yonemitsu S, Masuzaki H, Ogawa Y, Hosoda K, Inoue G, Yoshimasa Y, Nakao K. Thyrotropin decreases leptin production in rat adipocytes. Metabolism 48:1570-1574, 1999
40. Masuzaki H, Ogawa Y, Aizawa-Abe M, Hosoda K, Suga J, Ebihara K, Satoh N, Iwai H, Inoue G, Nishimura H, Yoshimasa Y, Nakao K Glucose metabolism and insulin sensitivity in transgenic mice overexpressing leptin with lethal yellow agouti mutation: usefulness of leptin for the treatment of obesity-associated diabetes. Diabetes 48:1615-1622, 1999
41. Ogawa Y, Masuzaki H, Hosoda K, Aizawa-Abe M, Suga J, Suda M, Ebihara K, Iwai H, Matsuoka N, Satoh N, Odaka H, Kasuga H, Fujisawa Y, Inoue G, Nishimura H, Yoshimasa Y, Nakao K Increased glucose metabolism and insulin sensitivity in transgenic skinny mice overexpressing leptin. Diabetes 48:1822-1829, 1999
42. Itoh H, Doi K, Tanaka T, Fukunaga Y, Hosoda K, Inoue G, Nishimura H, Yoshimasa Y, Yamori Y, Nakao K Hypertension and insulin resistance: role of peroxisome proliferator-activated receptor gamma. Clin Exp Pharmacol Physiol 26: 558-560, 1999
43. Shintani M, Nishimura H, Yonemitsu S, Ogawa Y, Hosoda K, Inoue G, Yoshimasa Y, Nakao K. TSH and Leptin. Downregulation of leptin by free fatty acids in rat adipocytes:Effects of triacsin C,palmitate,and 2-bromopalmitate. Metabolism:Clinical & Experimental.,49(3): 326-330 Mar 2000.
44. Kan S, Onodera H, Furutani E, Aung T, Araki M, Nishimura H, Maetani S, Imamura M: Novel Control System for Blood Glucose using a Model Predictive Method ASAIO Journal (American Society for Artificial Organs) 46:657-662, 2000
45. Yamamoto Y, Yoshimasa Y, Koh M, Suga J, Masuzaki H, Ogawa Y, Hosoda K, Nishimura H, Watanabe Y, Inoue G, Nakao K. Constitutively active mitogen-activated protein kinase kinase increases GLUT1 expression and recruits both GLUT1 andGLUT4 at the cell surface in 3T3-L1 adipocytes. Diabetes. 49(3):332-9, 2000
46. Cheol Son, Kiminori Hosoda, Junichi Matsuda, Junji Fujikura, Hiroshi Iwakura, Shin yonemitsu, Haruo Nishimura. Upregulation of UCP3 Gene Expression by Fatty Acids Via Peroxisome Proliferator-Activated Receptor in L6 Myptubes. Diabetes 49(S): 61, 2000
47. Yonemitsu S, Nishimura H, Shintani M, Masuzaki H, Ogawa Y, Hosoda K, Inoue G, Hayashi T, Nakao K. Troglitazone induces GLUT4 translocation in L6 Myotcytes. Diabetes 50(5): 1093-1101, 2001
48. Shintani M, Nishimura H, Yonemitsu S, Ogawa Y, Hosoda K, Hayashi T, Inoue G, Nakao K. Troglitazone not only increases GLUT4 but also induces its translocation in rat adipocytes. Diabetes 50 (10): 2296-2300, 2001
49. Son C, Hosoda K, Matsuda J, Fujikura J, Yonemitsu S, Iwakura H, Masuzaki H, Ogawa Y, Hayashi T, Itoh H, Nishimura H, Inoue G, Yoshimasa Y, Yamori Y, Nakao K. Up-regulation of uncoupling protein 3 gene expression by fatty acids and agonists for PPARs in L6 myotubes. Endocrinology 142 (10): 4189-4194, 2001
50. Miyawaki T, Masuzaki H, Ogawa Y, Hosoda K, Nishimura H, Azuma N, Sugawara A, Masuda I, Murata M, Matsuo T, Hayashi T, Inoue G, Yoshimasa Y, Nakao K. Clinical implications of leptin and its potential humoral regulators in long-term low-calorie diet therapy for obese humans. Eur J Clin Nutr. 56(7) :593-600, 2002
51. Nishimura H, Shintani M, Maeda K, Okuda J.Satski Tanaka. Multiple Effects of Nateglinide on Glucose Metabolism in Obese Patients with Type 2 Diabetes Mellitus. Diabetes 51S-2: A609, 2002
52. Iwakura H, Hosoda K, Doi R, Komoto I, Nishimura H, Son C, Fujikura J,Tomita T, Takaya K, Ogawa Y, Hayashi T, Inoue G, Akamizu T, Hosoda H,Kojima M, Kangawa K, Imamura M, Nakao K. Ghrelin expression in isletcell tumors: augmented expression of ghrelin in a case of glucagonoma with multiple endocrine neoplasm type I. J Clin Endocrinol Metab 87(11): 4885-8, 2002
53. Haruo Nishimura, Mitsuyo Shintani, Kouji Maeda Possile Exrtra-pancreaic Effects of Nateglinide on Glucose Metabolism in Type 2 Diabetes Mellitus Diabetes, 52(S1), A461, 2003
54. Haruo Nishimura, Daisuke Aotani, Atsuo Nakano, Mitsuyo Shintani, Kouji Maeda Insulin-sensitzing Effects of Nateglinide on Type 2 Diabetes Mellitus Diabetes 53, A484, 2004
55. H. Nishimura (in MEGA Study Group) (MEGA: Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese ) Design and Baseline Characteristics of a Study of Primary Prevention of Coronary Events With Pravastatin Among Japanese With Mildly Elevated Cholesterol Levels Circulation Journal, 68(9), 860-867, 2004
56. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Haruo Nishimura et al. for the MEGA Study Group The Lancet ; 368: 1155-1163, 2006
57. Hepatic safety profile and glycemic control of pioglitazone in more than 20,000 patients with type 2 diabetes mellitus: Postmarketing surveillance study in japan Ryzo Kawamori et all. on behalf of the PRACTICAL Study Group( including H. Nishimura) Diabetes Research and Clinical Practice 76,229-235, 2007
58. Does multiple injection therapy (MIT) with an ultrarapid-acting insulin analogue prevent cardiovascular disease in type 2 diabetes? -The NICE-study: a prospective, randomised, open-label, blinded endpoint study. HARUO NISHIMURA, MITSUYO SHINTANI, KOJI MAEDA, OTOSHI MAKOTO, HIDESHI KUZUYA Diabetes 57, Sup 1, A49, 2008
59. Does multiple injection therapy (MIT) with an ultrarapid-acting insulin analogue prevent cardiovascular disease in type 2 diabetes? -The NICE-study: a prospective, randomised, open-label, blinded endpoint study. H. Nishimura, M. Shintani, K. Maeda, I.Hanaoka, H. Kuzuya Diabetologia 51, Sup 1, S543 (#1349), 2008
60. Does multiple injection therapy (MIT) with an ultrarapid-acting insulin analogue prevent cardiovascular disease in type 2 diabetes? -The NICE-study: a prospective, randomised, open-label, blinded endpoint study. HARUO NISHIMURA, MITSUYO SHINTANI, KOJI MAEDA, OTOSHI MAKOTO, HIDESHI KUZUYA Diabetologia, 2009
61. Effects of cilostazol on insulin action in type 2 Diabetic patients. Haruo Nishimura, Mitsuyoshintani, Yukiko Yosida, Reiko Tomita, Atsusi Nakano, Daisuke Aotani, Kouji Maeda Ｄｉａｂｅｔｅｓ（in print) 2009
62. Rapid-acting insulin aspart reduces cardiovascular complications and costs in type 2 diabetes when compared with human insulin R.FPollock, W.J.Valentine, T.L.Thomsen, H. Nishimura Diabetologia, 52, S349, 2009
63. Clinical characteristics of 4 cases of autoimmune pancreatitis with diabetes mellitus. Mitsyo Shinatani, Yukiko Yoshida, Koji Maeda, Reiko Tomita, Satsuki Tanaka, Kiyosi Ashida, Haruo Nishimura Endocrine Journal, 57, S401, 2010
64. The costeffectiveness of rapid-acting insulin aspart compared with human insulin in type 2 diabetes patients: an analysis from the Japanese third-party payer perspective R.F.Pollock, W.J.Valentine, T.Pilgaard, H. Nishimura J Medical Economics 14: 36-46, 2011
65. Which is a better treatment for hypertensive patients with diabetes: a combination of losartan and hydrochlorothiazide or a maximum dose of losartan? Nishimura H, Shintani M, Maeda K, Otoshi K, Fukuda M, Okuda J, Nishi S, Ohashi S, Kato S, Baba Y; Biriken Study Group. Clinical and Experimental Hypertension 35(8):582-588, 2013